Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NYMOX PHARMACEUTICAL CORPORATION

(NYMX)
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 09/16 11:41:10 am
2.075 USD   -3.49%
09/10NYMOX PHARMACEUTICAL : Files for Regulatory Approval of Fexapotide Triflutate Brand Names
MT
09/10NYMOX PHARMACEUTICAL : Provides Shareholder Update
AQ
08/13NYMOX : Q2 Earnings Snapshot
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 2000 Value Index

06/25/2021 | 12:00am EDT

Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 2000 Value Index


© S&P Capital IQ 2021
All news about NYMOX PHARMACEUTICAL CORPORATION
09/10NYMOX PHARMACEUTICAL : Files for Regulatory Approval of Fexapotide Triflutate Br..
MT
09/10NYMOX PHARMACEUTICAL : Provides Shareholder Update
AQ
08/13NYMOX : Q2 Earnings Snapshot
AQ
08/13Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quar..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell Small Cap Comp..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000 Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000E Growth I..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 2500 Growth In..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000E Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000 Growth In..
CI
More news
Financials (USD)
Sales 2020 0,01 M - -
Net income 2020 -11,7 M - -
Net cash 2020 3,19 M - -
P/E ratio 2020 -15,6x
Yield 2020 -
Capitalization 180 M 180 M -
EV / Sales 2019 1 283x
EV / Sales 2020 37 731x
Nbr of Employees -
Free-Float 51,7%
Chart NYMOX PHARMACEUTICAL CORPORATION
Duration : Period :
Nymox Pharmaceutical Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NYMOX PHARMACEUTICAL CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Paul Averback Chairman, President & Chief Executive Officer
Erik Danielsen Chief Financial Officer
Randall J. Lanham COO, Secretary, Director & General Counsel
David S. Morse Independent Director
James G. Robinson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NYMOX PHARMACEUTICAL CORPORATION-13.31%180
MODERNA, INC.315.87%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.44.30%49 541
CELLTRION, INC.-24.09%31 848
SEAGEN INC.-13.16%27 670